Sjogren's Syndrome Market

 Market Overview:

The 7 major Sjogren's syndrome markets reached a value of US$ 168.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 226.0 Million by 2034, exhibiting a growth rate (CAGR) of 2.69% during 2024-2034.

The Sjogren's syndrome market has been comprehensively analyzed in IMARC's new report titled "Sjogren's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sjogren's syndrome is an autoimmune disorder that primarily affects the exocrine glands in the body responsible for producing saliva, sweat, tears, etc. The condition is characterized by inflammation that damages the glands and reduces their ability to create fluids, leading to dryness of the mucous membranes. The symptoms can vary widely from person to person, but the hallmark feature of the condition is dryness of the mouth and eyes. This can lead to discomfort, difficulty swallowing, and an increased risk of dental decay and infection. Several other indications can include joint pain and stiffness, skin rashes, fatigue, etc. In severe cases, Sjögren's syndrome may also cause damage to the kidneys, lungs, and nervous system. Diagnosis often involves a combination of medical history, physical examination, and laboratory procedures. These may consist of blood tests to detect specific antibodies associated with the condition, eye tests to evaluate tear production and dryness, and a biopsy of the salivary gland to check for inflammation and damage. Additionally, various imaging studies, such as an ultrasound or MRI, may be used to assess gland function and identify any structural abnormalities.

The increasing cases of immune system dysfunction, which leads to the inflammation of moisture-producing glands in the body, are primarily driving the Sjogren's syndrome market. Apart from this, the rising incidences of several environmental factors, such as viral infections, exposure to toxins and pollutants, stress, etc., that trigger the development of the illness in people who are genetically predisposed to it, are also bolstering the market growth. Furthermore, the widespread adoption of saliva substitutes in the form of sprays, gels, and lozenges to relieve dryness in the mouth is creating a positive outlook for the market. Besides this, the escalating utilization of punctal plugs, which are small devices placed in the tear ducts to stop tears from draining away too quickly, is also augmenting the market growth. Additionally, numerous key players are making extensive investments in research activities to develop immunomodulatory drugs that reduce inflammation and enhance moisture production in patients with Sjogren's syndrome. This, in turn, is acting as another significant growth-inducing factor. Moreover, the increasing usage of salivary gland scintigraphy for identifying abnormalities and assessing the function of moisture-producing glands is expected to drive the Sjogren's syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Sjogren’s syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Sjogren’s syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Sjogren’s syndrome market in any manner.

Recent Developments:

• In June 2024, Johnson & Johnson reported that patients treated with nipocalimab showed a statistically significant and clinically meaningful improvement in ClinESSDAIa score compared to placebo at 24 weeks versus baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging trial of nipocalimab in adult patients with Sjogren's syndrome. Response was seen as early as Week 4 and increased throughout the 24-week treatment period compared to those receiving placebo.
• In April 2024, Kiniksa Pharmaceuticals, Ltd. announced plans to conduct a Phase 2b trial of abiprubart in Sjogren's syndrome. Abiprubart is a humanized anti-CD40 monoclonal antibody being studied for its ability to disrupt the interaction between CD40 and CD154 (CD40 ligand).
• In March 2024, argenx SE disclosed its plan to continue the development of efgartigimod to Phase 3 in adults suffering from primary Sjogren’s syndrome, following the analysis of topline data from the Phase 2 RHO trial study.
• In November 2023, Amgen released additional findings from its Phase 2 research testing dazodalibep, an experimental medication, for the treatment of Sjogren's syndrome. These findings will be presented at the American College of Rheumatology (ACR) Convergence 2023, which takes place in San Diego from November 10-15. The study's findings show that dazodalibep may alleviate both the systemic and symptomatic disease burden in two different patient categories.

Key Highlights:

• Primary Sjogren syndrome primarily affects women, with the age at disease start and systemic activity differing by geographical origin.
• The female-to-male ratio for this illness is observed to be 9:1.
• The prevalence of primary Sjogren syndrome varies depending on the study methodology, although it can be estimated at 0.01% to 0.05%.
• Sjogren syndrome affects persons of all ages, however it is more common in the elderly. Onset usually occurs in the fourth or fifth decade of life.
• Mortality in primary Sjogren syndrome appears to be highest in patients with extra-glandular symptoms, lung involvement, and non-Hodgkin lymphoma.

Drugs:

Cevimeline is used to alleviate the dry mouth symptoms that Sjogren's syndrome patients frequently suffer. It works by inducing specific glands in the mouth to generate more saliva. The recommended dosage of cevimeline is 30 mg orally three times per day.

Ianalumab is an antibody that targets the B-cell activating factor receptor (BAFF-R). It is intended to disrupt BAFF-R-mediated signaling and decrease B-cells by antibody-dependent cellular cytotoxicity. It is being examined in several Phase 3 studies, notably for Sjogren's syndrome.

RSLV-132 is an Fc fusion protein made up of catalytically active human RNase linked with human IgG1.  The medicine is intended to digest the RNA molecules associated with the autoantibodies that are present in the circulation of individuals with autoimmune illnesses such as Sjogren's syndrome.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Sjogren's syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Sjogren's syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Sjogren's syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Sjogren's syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Sjogren's syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Sjogren's syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Sjogren's syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Sjogren's syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Sjogren's syndrome by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Sjogren's syndrome by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with Sjogren's syndrome across the seven major markets?
• What is the size of the Sjogren's syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Sjogren's syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Sjogren's Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Sjogren's syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Sjogren's syndrome market?
• What are the key regulatory events related to the Sjogren's syndrome market?
• What is the structure of clinical trial landscape by status related to the Sjogren's syndrome market?
• What is the structure of clinical trial landscape by phase related to the Sjogren's syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Sjogren's syndrome market?